ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
This weekend’s oncology conference will feature at least 30 different ADC projects.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.